Please login to the form below
GSK sells Italian research unit to Aptuit
GSK is to sell its Medicines Research Centre in Verona, Italy to Aptuit Inc who will continue to employ all 500 staff who work at the centre
Aptuit will supply GSK with R&D services from the facilities. The acquisition will allow Aptuit to provide integrated development services to its global customers while keeping the existing pool of life science research experts in Italy.
The financial terms of the deal have not been disclosed.
In February 2010, GSK announced plans to cease discovery research in selected neuroscience areas, including depression and pain, to focus on neurodegenerative and neuroinflammatory diseases like Alzheimer's disease, multiple sclerosis and Parkinson's disease. These plans have a direct impact on the Italian R&D facility.
Aptuit specialises in providing contract development and manufacturing services to the pharmaceutical and biotech sectors. This latest acquisition will bring their global portfolio total to 19 locations.
Share
Related Hub content
COVID-19 Updates and Daily News
Featured jobs
- Senior Consultant, Pricing & Market Access Consultancy, circ...
-
circa £100K package
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
-
Events Executive
-
Depending on Experience
- Project Director, Healthcare Marketing Agency patient focus Lond...
-
Highly competitive salary
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- Digital Project Director, Healthcare Marketing Agency patient fo...
-
Highly competitive salary
-
Digital account director
-
Competitive
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- AZ publishes new real-world safety data for COVID-19 vaccine Vaxzevria
- Understanding the ‘real world’ starts and ends with the patient
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- Sanofi raises profit forecast following positive Q2 results
- Biogen and Eisai present new data for controversial Alzheimer's drug Aduhelm at AAIC
- Investors respond positively to “strong” Eli Lilly results
- Sanofi to buy mRNA tech partner, Translate Bio, for $3.2bn
- Novartis to proceed with phase 3 trial for intrathecal OAV-101 in older SMA patients
- Ask the writers: Transitioning from academia to medical writing
- Strategic launch planning: familiar framework, new mindset
- OPEN Health acquires UK medical communications agency Spirit
- The future of office working designed with our people in mind: ‘Work Where You Work Best’, an Evoke KYNE model
- Recruiting patients for real-world studies – the power of a digital campaign
- J&J and Pfizer quietly resolve Remicade biosimilar lawsuit
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- The future of work has been just around the corner for some time...
- Employee wellbeing in creative agencies: three tips to get you started
PMHub
McCann Health Medical Communications
We are the medical communications experts within McCann Health. Communicating science to bring meaning and positive change to people’s lives....
Latest intelligence
- Ask the writers: Transitioning from academia to medical writing
- Porterhouse Medical's talented writers talk about their transition from academia and give advice to those people considering a career in medical writing...
- Strategic launch planning: familiar framework, new mindset
- By James Aird...
- Guide
- How to embrace behavioural science principles in healthcare MR...
